Please assess the completion status of the following clinical trial:

Trial Title: Iron Treatment of Sleep Disorders in Children With Autism Spectrum Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Child has a clinical diagnosis of autism spectrum disorder, meeting Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria, confirmed by the Autism Diagnostic Observation Schedule.~* Age 2 years to 10 years 11 months.~* Child has sleep onset latency of greater than 40 minutes on 3 or more nights per week, an average greater than 30 minutes per night, or night waking at least 3 times per week requiring parental intervention or lasting \>20 minutes per night.~* A mean sleep latency of 30 minutes or more, or night waking will be need to be confirmed by 7 days of scorable actigraphy data prior to randomization.~* Ferritin between 17ng/ml and 49 ng/ml, confirmed at a central lab.~* The child has been screened for medical conditions that affect sleep by their clinician and referred for subspecialty evaluation, as needed, for coexisting disorders (e.g., Gastrointestinal reflux disease, epilepsy).~* We will include children with coexisting medical, psychiatric, and neurological disorders as long as they have been evaluated by a physician and a treatment plan has been implemented, with the child on a stable dose of medication for one month~* Parents and their child are willing and able to provide informed consent (and assent, depending on child's age and cognitive function) and to cooperate with study procedures. Children with coexisting intellectual disability who can cooperate with study procedures are eligible.~* A child with known genetic syndromes comorbid with autism spectrum disorder (ASD), including Fragile X, down syndrome, neurofibromatosis, or tuberous sclerosis will be included as long as they meet other eligibility criteria.~Exclusion Criteria:~* Family history of hemochromatosis~* Elevated C-reactive protein (CRP) (may be repeated and enrolled once inflammation has resolved)~* Anemia - low hemoglobin (\<11.0 g/dL for children \<5 and \<12.0 g/dL for children 6-11) (unless cause of anemia is known, is not due to iron deficiency, and there would be no contraindication to treatment with iron.)~* Fever in past week or active infection.~* Current treatment with iron in any amount other than that in a multivitamin~* Severe constipation/GI issues that are not adequately managed~* Treatable sleep and medical condition such as obstructive sleep apnea or severe eczema that are not adequately managed.~* A child who is currently participating in other interventional research studies.~* Child with a seizure in the previous 2 years.~* A child taking medications that significantly influence RLS symptoms such as antinausea drugs (prochlorperazine, promethazine, triethylpyrazine or metoclopramide), antipsychotic drugs (haloperidol or phenothiazine derivatives such as chlorpromazine, promazine, triflupromazine, methotrimeprazine, fluphenazine, mesoridazine, perphenazine, thioridazine, and trifluoperazine), antidepressants that increase serotonin only if the onset of sleep issues was associated with starting the medication, and some cold and allergy medications-that contain sedating antihistamines(methdilazine, promethazine, trimeprazine).~* A child taking a medication that has a significant drug interaction with iron that cannot be addressed by the timing of administration such as Cholestyramine and Colestipol, Tagamet, Zantac, Pepcid, Axid, ACE inhibitors (captopril, enalapril, and lisinopril), carbidopa, levodopa, levothyroxine, tetracyclines, and quinolones.~* Girls who have started menstruating.~* Inability or unwillingness of subject or legal guardian/representative to give written informed consent.~* Allergic to turmeric (natural dye used in placebo).~* Allergy to prilocaine/lidocaine, if the participant requires it for procedures~* The onset of sleep symptoms was related to the onset of puberty.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Ferrous Sulfate (Type: EXPERIMENTAL): 3mg/kg divided twice per day, 30 minutes before a meal or 2 hours after a meal
- Placebo (Type: PLACEBO_COMPARATOR): Equivalent volume of liquid placebo administered twice daily, before a meal or 2 hours after a meal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete